This study was undertaken to determine the feasibility of dose escalation using proton therapy, as compared to conventional 3-dimensional conformal radiation, by minimizing the dose to normal tissues.
NRG Oncology RTOG 0529 assessed the feasibility of dose-painted intensity modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer.
These findings have stimulated interest in assessing the feasibility of dose escalation using a modified CHART schedule.
In the study of van Gelder et al., the feasibility of dose reduction from 100 mAs to 50 mAs and 30 mAs was evaluated [ 24].
Chao et al.[ 17 ] examined the feasibility of dose-escalation to hypoxic areas using IMRT by co-registration of Cu-ATSM PET to CT images for treatment planning.
Exploring the feasibility of dose reduction in clinical CT can be done in appropriately designed clinical studies and was first described by Mayo et al. [ 3].
We investigated the feasibility of dose-dense neoadjuvant chemotherapy (NACT) with paclitaxel and carboplatin before radical chemoradiation (CRT) and assessed the response rate to such a regimen.
The present study aims to document the efficacy and feasibility of dose-intensive epidoxorubicin in combination with a standard dose of 5-fluorouracil and cyclophosphamide as up-front chemotherapy in this setting.
Nevertheless, we have demonstrated the feasibility of dose-escalating topotecan in the setting of AHSCT in combination with carboplatin and cyclophosphamide and this may have applicability in other tumor settings.
Indeed the feasibility of dose-dense chemotherapy incorporating a taxane within an anthracycline-based polychemotherapy backbone remains unclear and depends on careful regimen design and a justified therapeutic ratio.
Feasibility of dose escalation was determined based on safety, tolerability, and PK data review by the sponsor and an independent, external physician, who did not participate in the study, after all patients within a cohort had completed at least two chemotherapy cycles (one cycle without and one cycle with eltrombopag/placebo) and when all patients finished all treatment cycles.
